[go: up one dir, main page]

ATE458491T1 - Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin - Google Patents

Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Info

Publication number
ATE458491T1
ATE458491T1 AT06802456T AT06802456T ATE458491T1 AT E458491 T1 ATE458491 T1 AT E458491T1 AT 06802456 T AT06802456 T AT 06802456T AT 06802456 T AT06802456 T AT 06802456T AT E458491 T1 ATE458491 T1 AT E458491T1
Authority
AT
Austria
Prior art keywords
oxytocin
administration
treating headache
headache
treatment
Prior art date
Application number
AT06802456T
Other languages
English (en)
Inventor
David Yeomans
Martin Angst
William Frey
Daniel Jacobs
Original Assignee
Univ Leland Stanford Junior
Healthpartners Res Foundation
Trigemina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Healthpartners Res Foundation, Trigemina Inc filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE458491T1 publication Critical patent/ATE458491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06802456T 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin ATE458491T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71195005P 2005-08-26 2005-08-26
US79400406P 2006-04-21 2006-04-21
PCT/US2006/033500 WO2007025249A2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin

Publications (1)

Publication Number Publication Date
ATE458491T1 true ATE458491T1 (de) 2010-03-15

Family

ID=37654909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06802456T ATE458491T1 (de) 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Country Status (9)

Country Link
US (9) US20070093420A1 (de)
EP (3) EP2179741B1 (de)
JP (4) JP5276982B2 (de)
AT (1) ATE458491T1 (de)
AU (1) AU2006282799B2 (de)
CA (2) CA2620202C (de)
DE (1) DE602006012513D1 (de)
IL (1) IL189777A0 (de)
WO (2) WO2007025286A2 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
ATE458491T1 (de) * 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
AU2006304392B2 (en) * 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2680704A1 (en) * 2007-03-12 2008-09-18 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
EP2583550A1 (de) * 2007-03-13 2013-04-24 National Jewish Health Verfahren zur Erzeugung von Antikörpern
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
CA2687505C (en) * 2007-06-08 2013-10-08 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US20100221200A1 (en) * 2007-07-17 2010-09-02 The Ohio State University Research Foundation Compositions and methods for skin care
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
AU2008303945A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100234306A1 (en) * 2007-09-11 2010-09-16 Dorian Bevec Use of a peptide as a therapeutic agent
RU2010113977A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
KR20100075438A (ko) * 2007-09-11 2010-07-02 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US20110117106A1 (en) * 2008-03-06 2011-05-19 Alice Prince Uses of calpain inhibitors to inhibit inflammation
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
SG10201803982TA (en) * 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
AU2009274172B2 (en) * 2008-07-21 2015-08-13 Htyr Acquisition Llc Differentiated anucleated cells and method for preparing the same
EP2966084B1 (de) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zur verwendung davon und verfahren zur identifikation von mitteln zur myc-modulierung
WO2010029555A1 (en) * 2008-09-12 2010-03-18 Slender Medical, Ltd. Virtual ultrasonic scissors
US20110318345A1 (en) * 2008-09-15 2011-12-29 Optinose As Nasal delivery
CA2739936C (en) * 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
EP2373680A4 (de) 2008-12-08 2017-05-24 Biousian Biosystems, Inc Selektive delta-opioidrezeptor-analgetika
CN102405044A (zh) * 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
SG176000A1 (en) * 2009-05-13 2011-12-29 Protein Delivery Solutions Llc Pharmaceutical system for trans-membrane delivery
JP5669145B2 (ja) * 2009-07-02 2015-02-12 国立大学法人山口大学 表面麻酔剤
SG177752A1 (en) 2009-07-27 2012-03-29 Trigemina Inc Methods for treatment of pain
FR2948809B1 (fr) * 2009-07-31 2012-08-17 St Microelectronics Rousset Amplificateur de lecture faible puissance auto-minute
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
PH12012500485A1 (en) 2009-09-08 2012-10-22 Signature Therapeutics Inc Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
AU2010330747B2 (en) * 2009-12-18 2016-08-11 Achelios Therapeutics, Inc. Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
US20110184322A1 (en) * 2010-01-22 2011-07-28 Slender Medical Ltd. Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
WO2011133179A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable hydromorphone prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US9242122B2 (en) 2010-05-14 2016-01-26 Liat Tsoref Reflectance-facilitated ultrasound treatment and monitoring
US8617150B2 (en) 2010-05-14 2013-12-31 Liat Tsoref Reflectance-facilitated ultrasound treatment
US8956346B2 (en) 2010-05-14 2015-02-17 Rainbow Medical, Ltd. Reflectance-facilitated ultrasound treatment and monitoring
EP2571511B1 (de) 2010-05-18 2014-10-08 Université de Genève Neue verwendungsarten für oxytocin-like-moleküle und zugehörige verfahren
WO2012003968A1 (en) * 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES3034958T3 (en) 2010-08-27 2025-08-27 Univ Southern California Pharmaceutical compositions comprising derivatives of perillyl alcohol
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
US8647661B1 (en) * 2010-11-05 2014-02-11 Florida A&M University Surface modified multilayered nanostructures for dermal delivery
US9211269B2 (en) 2010-12-17 2015-12-15 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
RU2609412C2 (ru) 2011-01-11 2017-02-01 Сигничер Терапьютикс, Инк. Композиции, содержащие расщепляемое ферментами пролекарство оксикодона
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10687975B2 (en) * 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CN103813800B (zh) 2011-03-09 2017-12-19 特色疗法股份有限公司 具有杂环连接物的活性剂前药
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
EP3449917A3 (de) 2011-04-05 2019-06-05 Grünenthal GmbH Tapentadol zur vorbeugung der schmerzchronifizierung
PL2694050T3 (pl) * 2011-04-05 2020-03-31 Grünenthal GmbH Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
HRP20171570T1 (hr) 2011-04-29 2017-11-17 Grünenthal GmbH Tapentadol za sprječavanje i liječenje depresije i tjeskobe
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
WO2013067309A1 (en) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
CA2856451A1 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating pain by administration of nerve growth factor
US9707414B2 (en) 2012-02-14 2017-07-18 Rainbow Medical Ltd. Reflectance-facilitated ultrasound treatment and monitoring
US9308163B2 (en) 2012-02-15 2016-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
CN110643576A (zh) 2012-07-20 2020-01-03 泰加生物工艺学公司 造血区室的增强的重建和自动重建
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
US10004557B2 (en) 2012-11-05 2018-06-26 Pythagoras Medical Ltd. Controlled tissue ablation
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014085571A1 (en) * 2012-11-28 2014-06-05 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor
US9050330B2 (en) * 2012-12-06 2015-06-09 Jose C. Ramon-de-Jesus Method, composition and kit for treating frequent headaches
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EA032830B1 (ru) 2013-03-15 2019-07-31 Эмджен Инк. Антитела к pac1 человека и их применение для лечения головной боли
SG11201509419QA (en) 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3139853B1 (de) 2014-05-07 2018-12-19 Pythagoras Medical Ltd. Apparat zur gesteuerten gewebeablation
US20150359738A1 (en) * 2014-06-16 2015-12-17 Loewi LLC Methods of Anesthetizing Nerve Tissue in the Trigeminal Nerve Pathway and Medical Uses Thereof
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JP6607508B2 (ja) * 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
RU2701199C2 (ru) * 2014-10-01 2019-09-25 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
EP3848028B9 (de) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Verfahren zur behandlung von augenleiden
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
EP3209803A4 (de) 2014-10-21 2018-06-13 Ubiome, Inc. Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika
CA2966802C (en) 2014-11-19 2022-11-15 Optinose As Intranasal administration
JP2017536421A (ja) * 2014-12-01 2017-12-07 アケリオス セラピューティクス，インコーポレーテッド 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
US11389473B2 (en) * 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP6674957B2 (ja) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． ペリリルアルコール誘導体を含む医薬組成物
WO2016140063A1 (ja) * 2015-03-04 2016-09-09 栄研化学株式会社 オキシトシンの高感度測定法
JP6924148B2 (ja) 2015-04-16 2021-08-25 ハー・ルンドベック・アクチエゼルスカベット 抗ｐａｃａｐ抗体及びそれらの使用
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
SMT202500100T1 (it) 2016-04-12 2025-05-12 Tonix Pharma Ltd Formulazioni di ossitocina contenenti magnesio e metodi d'uso
BR112018071156A2 (pt) 2016-04-15 2019-03-12 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
KR20190005873A (ko) 2016-04-15 2019-01-16 앨더 바이오파마슈티컬즈, 인코포레이티드 항-pacap 항체 및 그의 용도
EP3457975A2 (de) 2016-05-18 2019-03-27 Pythagoras Medical Ltd. Spiralförmiger katheter
FI3515937T3 (fi) 2016-09-23 2026-02-11 Teva Pharmaceuticals Int Gmbh Refraktaarisen migreenin hoito
WO2018094376A1 (en) * 2016-11-21 2018-05-24 uBiome, Inc. Method and system for characterizing a headache-related condition
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR102883778B1 (ko) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
DK3749291T3 (da) 2018-02-08 2024-04-08 Univ Southern California Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法
WO2021016190A1 (en) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for modulating drug-use disorders
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
JP2022546703A (ja) * 2019-08-29 2022-11-07 ニューヨーク ユニバーシティ 耳鳴りの治療のためのオキシトシン組成物
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CA3189263A1 (en) * 2020-08-10 2022-02-10 Ziropa, Inc. Compositions and methods for topical delivery
WO2023055830A1 (en) 2021-09-29 2023-04-06 Ensysce Biosciences, Inc. Enzyme-cleavable methadone prodrugs and methods of use thereof
US20250099532A1 (en) * 2022-01-27 2025-03-27 Belnap Pharmaceuticals, Llc Methods of treatment using oxytocin
AU2023375349A1 (en) * 2022-11-07 2025-05-22 AEON Biopharma, Inc. Compositions for use in treating headache disorders
WO2025064708A1 (en) * 2023-09-22 2025-03-27 The George Washington University Compositions comprising oxytocin and methods of treating opioid overdose
WO2025199179A2 (en) 2024-03-18 2025-09-25 Tonix Pharmaceuticals Holding Corp. Oxytocin peptide analogs

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US464378A (en) * 1891-12-01 Toilet-paper holder
US6413A (en) * 1849-05-01 Improved method of making wire-strengthened spoons
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) * 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) * 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
EP0223831B1 (de) 1985-05-22 1992-07-15 Liposome Technology, Inc. Verfahren und system zum einatmen von liposomen
HU206890B (en) * 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
JP2851627B2 (ja) * 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
ATE156704T1 (de) * 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
DE4312913A1 (de) * 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
EP0800828A4 (de) * 1994-12-28 1999-03-31 Teikoku Hormone Mfg Co Ltd Transmucosale zubereitung
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CN1155368C (zh) * 1996-02-27 2004-06-30 帝人株式会社 鼻腔给药的粉剂组合物
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
EP1137401B1 (de) * 1998-12-09 2005-11-23 Chiron Corporation Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem
ATE289800T1 (de) 1998-12-09 2005-03-15 Chiron Corp Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
KR20020016831A (ko) * 1999-06-16 2002-03-06 나스텍 파마수티컬 컴퍼니 인코포레이티드 비내용 모르핀을 함유하는 의약 조성물 및 그 제조방법
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) * 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
KR20030060771A (ko) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
EP1370282A2 (de) * 2000-10-13 2003-12-17 Chiron Corporation Methode zur behandlung ischämischer zustände die das zentrale nervensystem beeinflussen
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
JP2005500258A (ja) * 2001-03-23 2005-01-06 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002086105A1 (en) 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
JP2005524649A (ja) * 2002-02-25 2005-08-18 カイロン コーポレーション Ｍｃ４−ｒアゴニストの鼻腔内投与
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
WO2003089456A2 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
EP1504268A2 (de) 2002-05-02 2005-02-09 Bayer HealthCare AG Diagnostika und therapeutika für krankheiten, die mit dem oxytocin rezeptor (oxtr) assoziiert sind
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
WO2004019875A2 (en) 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
US7065445B2 (en) * 2002-11-27 2006-06-20 Mobilearia Vehicle passive alert system and method
WO2004062563A2 (en) 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
ATE410170T1 (de) * 2003-03-27 2008-10-15 Pantarhei Bioscience Bv Verwendung von estrogenen zur behandlung von männerunfruchtbarkeit
KR101184833B1 (ko) 2003-04-08 2012-09-20 바이오템프트, 비.브이. Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
WO2004093145A2 (en) * 2003-04-11 2004-10-28 Paratek Microwave, Inc. Voltage tunable photodefinable dielectric and method of manufacture therefore
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005115370A2 (en) 2004-04-23 2005-12-08 The Regents Of The University Of California Compounds and methods for treating non-inflammatory pain using pparalpha agonists
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
BRPI0608309A2 (pt) * 2005-02-23 2009-12-08 Alza Corp administração intranasal de agentes ativos ao sistema nervoso central
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US20060252685A1 (en) * 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
ATE458491T1 (de) * 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
CN101404174B (zh) * 2007-10-04 2010-06-09 威刚科技股份有限公司 电子信息储存装置

Also Published As

Publication number Publication date
EP1928484B1 (de) 2010-02-24
DE602006012513D1 (de) 2010-04-08
WO2007025286A3 (en) 2007-05-10
CA2620364A1 (en) 2007-03-01
US8252745B2 (en) 2012-08-28
US20120028898A1 (en) 2012-02-02
JP2009506076A (ja) 2009-02-12
CA2620202A1 (en) 2007-03-01
IL189777A0 (en) 2008-08-07
CA2620202C (en) 2016-10-04
US8501691B2 (en) 2013-08-06
WO2007025286A2 (en) 2007-03-01
US20110250212A1 (en) 2011-10-13
JP5670415B2 (ja) 2015-02-18
US20120322736A1 (en) 2012-12-20
US20100080797A1 (en) 2010-04-01
AU2006282799B2 (en) 2012-11-29
WO2007025249A2 (en) 2007-03-01
US20090317377A1 (en) 2009-12-24
WO2007025249A3 (en) 2007-04-19
EP2056800A2 (de) 2009-05-13
US20070054843A1 (en) 2007-03-08
US8202838B2 (en) 2012-06-19
US8258096B2 (en) 2012-09-04
EP2179741A1 (de) 2010-04-28
JP5276982B2 (ja) 2013-08-28
EP2056800B1 (de) 2015-12-09
US20090291900A1 (en) 2009-11-26
EP1928484A2 (de) 2008-06-11
JP2013060464A (ja) 2013-04-04
US20070093420A1 (en) 2007-04-26
EP2179741B1 (de) 2014-10-15
JP2012207046A (ja) 2012-10-25
AU2006282799A1 (en) 2007-03-01
US20090181880A1 (en) 2009-07-16
US8198240B2 (en) 2012-06-12
JP2009506071A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE458491T1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EA201100748A1 (ru) Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
EP2054058A4 (de) Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005020580D1 (de) Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
EA201170698A1 (ru) Изоляция зон поглощения
EP4408412A4 (de) Zusammensetzungen und verfahren zur behandlung von kopfschmerzen
EP2037736A4 (de) Verfahren zur behandlung von zystennierenerkrankungen
NZ759585A (en) Agent for preventing or treating brain atrophy
ATE408627T1 (de) Verfahren zur entfernung von fibronektin aus plasmafraktionen
EP3927377A4 (de) Verfahren zur behandlung von infektionskrankheiten durch targeting des immun-checkpoints von nk-zellen
EA201590884A1 (ru) Способы лечения заболеваний печени
EP4419690A4 (de) Zusammensetzungen zur behandlung von cdkl5-mangelstörung (cdd)
ATE445644T1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties